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Background: Giant cell ependymoma of the filum terminale is a rare variant, generally manifested as a well-
circunscribed intradural mass with an indolent biological behavior.
Case presentation: We describe the case of a 48-year-old Mexican female who non-relevant past medical history,
that developed a GCE of the filum terminale. Magnetic resonance imaging and computed tomography revealed
the presence of an intra-axial tumor extending from L3 to L5 with extra-medullary invasion. Therefore the tumor
was considered unresectable and only incisional biopsy was obtained, establishing the tentative diagnosis of a
poorly differentiated neoplasia. A second evaluation of the case revealed the presence of numerous non-cohesive
pleomorphic giant cells with intranuclear inclusions and broad eosinophilic cytoplasm, alternating with intermediate
size cells with round, hyperchromatic nuclei and forming a perivascular pseudo-rosettes pattern. The ependymal
phenotype was supported by light microscopy and corroborated by immunohistochemistry analysis. The patient was
subsequently treated with radiotherapy 54Gy. She is alive after a 27-month follow-up, with residual disease, difficulty
ambulating and pain.
Conclusions: GCE of filum terminale may have an atypical clinical and radiological presentation, albeit with invasive
characteristics and anaplasia on histologic analysis. However, its biological behavior is indolent and associated to longer
survival. Due to the presence of giant cells, the differential diagnosis of other primary neoplasias at that site were
considered, including paraganglioma, malignant peripheral nerve sheath tumors as well as metastatic malignant
melanoma, adrenal carcinoma, thyroid gland carcinoma and urothelial carcinoma, that may all harbor giant cells.
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Ependymomas develop in the neuroaxis from the epen-
dymal cells lining the cerebral ventricles, the central
canal of the spinal cord, and the filum terminale. They
are rare slow-growing tumors representing 2 to 9% of all* Correspondence: fernando.candanedog@incmnsz.mx;
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(http://creativecommons.org/publicdomain/zeneuroepithelial tumors [1]. In adults, 60% of these tu-
mors are found in the spinal cord. The World Health
Organization (WHO) has sub-classified ependymomas
into cellular, papillary, clear cell, tanycytic, anaplastic,
and myxopapillary [1]. Giant cell ependymoma (GCE) is
an unusual ependymal tumor sub-type, only recently
recognized as diagnostic entity by Zec et al. [2] and it
has been included in the WHO classification. This vari-
ant is characterized by pleomorphic giant cells inter-
mingled with a typical ependymoma component. These
tumors may arise in the supra [3–5], and infratentorial
regions [3], the cervical spinal cord [3, 5–8], thoracicle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Age at presentation ranges between 5 and 89 years [2–10].
In spite of the presence of pleomorphic giant cells, the
prognosis has been relatively good in the few reported
cases of GCE [2–10]. Due to the rarity of this variant it is
difficult to define its clinicopathological and immuno-
histochemical features. Here, we describe the immu-
nohistochemical features of GCE of filum terminale
with high-grade histology, and its evolution over a long
follow-up period. Preliminary data were presented at the
XVIII International Congress of Neuropathology, Rio de
Janeiro, Brazil, 2014 [11] and at the 28th World Congress
of Pathology. Cancun, Mexico, 2015 [12].
Case presentation
A previously healthy, 48-years-old mexican woman was
admitted at the Hospital de Oncologia, Centro Medico
Nacional Siglo XXI, with left “pelvic limb” as well as
back pain, with loss of strength and balance. Physical
examination on admission revealed an ECOG of 1 and
difficulty ambulating. Muscle strength of the left lower
extremity was 3/5. No adenopathies were found in the
head and neck areas, and no tumor was identified in the
abdomen. Computed tomography (CT) scan revealed a
solid, heterogeneous, non-encapsulated, vascularized
intra-axial mass at the L3-L5 lumbar level, measuring
5.0x4.5 cm, that invaded the spinal canal and was fixed
to deep planes (Fig. 1a-d). Chest, abdominal and pelvic
CT scan revealed no abnormalities. A sagittal magnetic
resonance imaging (MRI) of the filum terminale
confirmed the presence of a large, expansive and infiltra-
tive spinal mass with associated bone remodelingFig. 1 Neuroimaging findings of the GCE from filum terminale. a-d Axial gad
non-encapsulated heterogeneously enhanced solid mass attached to the filumconditioning image reinforcement. The T2-weighted
MRI sequence showed a hyperintense tumor (Fig. 2a),
and the gadolinium-enhanced MRI scan revealed a large
infiltrative mass with highly heterogeneous signal
(Fig. 2b). Also, bilateral compression of the L3-L5 nerve
roots was evident. Neurologic examination uncovered
no other abnormalities. The imaging differential diagnosis
included that of a metastatic tumor. No laboratory abnor-
malities were reported. Laboratory thyroid function was
found T3 89.37 ng/dL (NL 80.00–200.00); T4 9.17 mcg/dL
(5.10–12.80); T4L 1.43 ng/dL (NL 0.90–1.70); TSH 0.764
uI/mL (NL 0.270–4.200); TG 9.26 ng/mL (NL 0.10–78.00),
vanillylmandelic acid 1.50 ng/mL (NL 1.50–4.8). Serum
epinephrine 113 pg/mL (NL 50.00–100.00), serum nor-
epinephrine 596 pg/mL (110.00–658.00), urinary epineph-
rine of 17.00 μg/day (NL 0.10–20.00), serum dopamine
12.00 pg/mL (NL 10.00–20.00), urinary dopamine of 0.60
μg/day (NL 0.29–1.87 μg/24 h), urinary norepineph-
rine of 96.00 μg/day (NL 10.00–70.00) and acid 5-
hidroxindolacetic of 3.00 mg/24 h. An octreoscan was
performed without evidence of involvement other
than in the lumbar region. Pre-operatively, the tumor
was considered completely unresectable and only inci-
sional biopsy was performed.
Pathologic findings
Incisional biopsy was obtained for intraoperative
evaluation. Macroscopically heterogeneous solid tumor
gray-white with areas of congestive appearance of
brown-reddish color was observed. Frozen sections
revealed a hypercellular tumor with solid growth and
encompassing two cell populations. The most strikingolinium-enhanced L3-L5-weighted CT image demonstrated an intradural
terminale
Fig. 2 Sagittal MRI showed a large infiltrative mass in the filum
terminale. a Hyperintensity MRI T2-weighted sequence; and
(b) Gadolinium-enhanced MRI scan showed a large infiltrative
mass with heterogeneous high signals
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hyperchromatic nuclei, with pseudoinclusions and abun-
dant eosinophilic cytoplasm. These cells were inter-
mingled with polygonal intermediate size cells with no
atypia, with hyperchromatic nuclei and scant eosinophilic
cytoplasm. Due to the observed degree of nuclear atypia
and pleomorphism, the intraoperatory diagnosis wasFig. 3 Histological findings of the GCE from filum terminale: a At low mag
immersed in a fibrillary stroma (Hematoxylin and eosin, 100X); b Neoplasia
fibrosis (Hematoxylin and eosin, 100X); c Perivascular pseudorosette and ep
(Hematoxylin and eosin 200X); d Low power view of pseudo-papillary arran
eosin 100X)reported as consistent with a poorly differentiated neuro-
endocrine carcinoma, metastatic to the lumbar spine.
However, in definitive sections a diagnosis of GCE was
rendered.
Microscopically, the tumor showed diffuse, solid, fes-
tooned, trabecular, nodular areas with increased cellularity
and a focal myxopapillary growth pattern (Fig. 3a-d). At
lower power, numerous non-cohesive pleomorphic giant
cells with abundant eosinophilic cytoplasm were observed.
Nuclei were large, round, hyperchromatic and displayed
intranuclear eosinophilic inclusions. They alternated with
polygonal medium-sized cells (Fig. 4a-b), forming perivas-
cular pseudorosettes and true rosettes (Fig. 4c-d). No
mitoses, microvascular proliferation nor necrosis in pseu-
dopalisading were observed.
Materials and methods
The tissue was fixed in 10% buffered formaldehyde and
paraffin embedded. Hematoxylin and eosin–stained
sections were used for diagnosis. For immunohistochem-
istry (IHC) analysis, 5-μm sections of a representative
block were obtained. The following antibodies were
used: CD34, c-Kit (CD117), inhibin, S100 protein, CD56,
chromogranin, synaptophysin, cytokeratin AE1/AE3,
epithelial membrane antigen (EMA), glial fibrillary acidic
protein (GFAP), CD99, bcl-2, HMB45, Melan A, PAX5,
cytokeratin 20, GATA3, uroplakin III, TTF-1, thyroglobu-
lin, cyclin-D1, p53 and Ki-67, which were performed on
an automated immunostainer (Ventana, Biotek System,nification neoplasia shows trabecular growth pattern and scalloping
shows solid growth pattern with formation of nodules surrounded by
endymal channels lined by monomorphic medium-sized cubic cells
gement in well-differentiated area of this tumor (Hematoxylin and
Fig. 4 Histological findings of the GCE from filum terminale: a-b Pleomorphic giant cells, with abundant eosinophilic cytoplasm, eccentrically
located single hyperchromatic large nuclei with prominent nucleoli, and intranuclear cytoplasmic inclusions (Hematoxylin and eosin, 400X);
c-d Perivascular pseudorosette and ependymal channels lined by monomorphic medium-sized cubic cells (Hematoxylin and eosin 200X)
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trol run concurrently. Briefly, paraffin sections were
mounted on charged glass slides, air-dried over-night, and
then deparaffinized. To enhance the immunostaining, a
heat-induced epitope-retrieval procedure was performed.
After incubation with bloking serum, sections were incu-
bated with primary antibodies (Table 1), followed by a bio-
tinylated polyvalent secondary antibody solution. Sections
were then incubated with horseradish peroxidase-
conjugated avidin-biotin complex, followed by 3,3-diami-
nobenzidine and hydrogen peroxidase.Results
Immunohistochemistry findings
Giant cells and pseudorosette-forming cells were CD56
(Fig. 5a) and GFAP positive (Fig. 5b). They also stained
multifocally for S-100 protein (Fig. 5c). A diffuse strong
membranous and cytoplasmic dot-like pattern expression
of CD99 was found (Fig. 5d). Both giant and small
neoplastic cells show positivity for bcl-2 (Fig. 5e). Also,
the small neoplastic cells showed nuclear positivity for
cyclin D1 and p53 (Fig. 5f). All other markers were
negative. The cell proliferation index analyzed by Ki-67
was 15% in the perivascular pseudo-rosette areas and
negative in the giant cells (Fig. 5g).
The patient was subsequently treated with spinal col-
umn radiotherapy, 54 Gy divided in 28 fractions decreased
her symptoms. Twenty-seven months after treatment, the
patient is alive, with residual diseases, difficulty ambulat-
ing and pain.Discussion
Ependymomas of the filum terminale represent 1 to 2%
of all spinal tumors, but the GCE is an extremely rare
variant [1]. Other than our reported case, 26 cases of
GCE have been described in the English literature [2–10].
However, this is the fifth case report of GCE originating in
the filum terminale [2, 5, 10]. Unlike the cases reported by
Zec et al. [2] ours had an unusual clinical and radiological
presentation with a non-encapsulated tumor infiltrating
extramedullary portion with soft tissue infiltration. Table 2
summarizes some characteristic of the informed cases of
GCE of the filum terminale. We also conducted a review
of literature in search of studies on GCE, focusing on the
IHC characteristics, but due to the rarity of this vari-
ant we found no studies analyzing immunohistochem-
ical markers. In order to identify markers that could
potentially be useful in the differential diagnosis with
other neoplasm with giant cells. This is the first
study that includes of the expression of CD56, CD99,
bcl-2 and cyclin D1 in addition to the GFAP and
S100 protein.
Clinical and radiological aspect of GCE of the filum ter-
minale is nonspecific, consisting of back pain with motor-
sensory deficit and may lead to a cauda equina syndrome.
MRI, it is the diagnostic test of choice because it allows
knowing the extent of the tumor, its relation to central
structures and nerve roots and it permits the evaluation of
the dissemination in subarachnoid space. MRI is typically
isointense in relation to the spinal cord on T1 and hyper-
intense on T2 sequences. Gadolinium-enhanced MRI
scans more frequently reveals ependymomas, which are
Table 1 Immunohistochemical antibodies used in this study
Antibody name Source Catalog Dilution Clone Staining pattern
Number
CD34 BioCare CM084C 1:200 QBEnd/10 Membranous
c-Kit BioSB BSS3221 1:100 4H2 Membranous,
cytoplasmic
Inhibin BioSB BSB5692 1:50 R1 Cytoplasmic
S100 protein BioSB BSB5922 1:100 4C4.9 Cytoplasmic,
nuclear
CD56 BioSB BSB5272 1:100 123C3DS Cytoplasmic,
membranous
Chromogranin BioSB BSB5349 1:300 LK2H10 Cytoplasmic
Synaptophysin BioSB BSB5950 1:300 Polyclonal Cytoplasmic
CK AE1/AE3 DAKO M351501 1:100 No clone Cytoplasmic
EMA Biogenex MU162UC 1:100 Mx5 Cytoplasmic,
membranous
GFAP Zymed 180021 1:100 ZCG-29 Cytoplasmic
CD99 BioSB BSB5314 1:50 CD99/B5 Cytoplasmic,
membranous
bcl-2 Cell Marque 226R-16 1:50 E17 Cytoplasmic
HMB45 DAKO M0634 1:100 HMB45 Cytoplasmic
Melan A Biocare CM125C 1:100 Melan-A A103 Cytoplasmic
PAX5 BioSB BSP5866 1:100 RBT-Pax-5 Nuclear
Uroplakin III Cell Marque 3454-16 1:50 AU-1 Cytoplasmic,
membranous
Cytokeratin 20 Biocare CM062C 1:100 Ks20.8 Cytoplasmic
GATA3 BioSB BSB2674 1:100 LSO-823 Nuclear
TTF-1 Zymed 18-0221 1:100 867G3/1 Nuclear
Thyroglobulin BioGenex MUD332UC 1:200 92H11 Cytoplasmic
Cyclin-D1 Biocare CRM307CK 1:100 SP4 Nuclear
p53 BioGenex ML236UC 1:500 DX7 Nuclear
Ki-67 Cell Marque 275R-16 1:150 SP6 Nuclear
c-kit CD117, CK Cytokeratin, EMA epithelial membrane antigen, GFAP glial fibrillary acidic protein
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sulated or heterogeneously (25%) enhanced by the con-
trast agent at a moderate or high intensity, which are not
encapsulated [13]. Thus, treatment is surgical with
complete resection of the tumors, yielding excellent out-
come [2]. However, in larger volume tumors, the pedicles
or the posterior vertebral body surface may be eroded.
Once the tumor breaks the capsule, it can infiltrate the
nerve roots, and this is associated with a high recurrence
rate and postsurgical neurologic deficit. Therefore, surgi-
cal treatment depends primarily on the size of the tumor
and is encapsulation. From an imaging viewpoint, in all
previously reported GCE cases, an intramedullary encap-
sulated mass has been observed in the filum terminale
with expansion of the cord [2, 5, 10]. In our case,
Gadolinium-enhanced MRI scan revealed a heteroge-
neously tumor measuring 5 cm in its greatest axis, non-encapsulated tumor and infiltrating and adhering to adja-
cent nerve tissue. Unfortunately, the tumor could not be
completely resected and only a biopsy was obtained for
histopathological diagnosis. The patient was only treated
with palliative radiotherapy for local disease control.
In general, there is no problem to make the diagnosis
of conventional ependymoma in morphological basis.
However, GCE is particularly difficult to recognize, espe-
cially in the filum terminale, as in our case. Zec et al. [2]
have proposed that the cellular pleomorphism present-
ing GCE is a result of degenerative changes. In our case,
the presence of giant pleomorphic cells could have led
to confusion with an anaplastic ependymoma. However,
we observed no mitotic activity, microvascular prolifera-
tion or necrosis with pseudopalisading pattern. Further,
we considered that finding giant cells with pseudoinclu-
sions intraoperatively study may be a distractor due to
Fig. 5 Immunohistochemical findings of the GCE from filum terminale. a All neoplastic cells show positivity for CD56, including giant cells;
b Both giant and medium-sized neoplastic cells show heterogeneous positivity for GFAP; c Neoplastic cells show intense positivity for S-100
protein; d Neoplastic cells also shows cytoplasmic positivity for CD99; e Both giant and medium-sized neoplastic cells shows positivity for bcl-2;
f Further medium-sized neoplastic cells shows nuclear positivivity for cyclin D1; g Neoplastic cells shows a cell proliferation index of 15%
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lead to the incorrect diagnosis of a high grade malignant
tumor; it may also delay a correct diagnosis, if not care-
fully observed adjacent areas, which are rosettes and
pseudorosettes that establish the diagnosis of GCE. It is
advisable to include the entire tissue to view the classic
ependymoma areas. The diagnosis of GCE is therefore,
still, a diagnosis of exclusion. The differential diagnosis
of GCE should initially include other intradural extrame-
dullary tumors, particularly those located in the lumbar
region, including some benign or malignant, primary or
metastatic, tumors both primary and metastatic, but his-
tologically characterized by the presence of giant cells.Table 2 Clinicopathological features of currently reported cases of G
Reference Gender Age Clinical features
1. Zec et al.
(1996) [2]
M 14
2. Zec et al.
(1996) [2]
M 14
3. Shintaku et al.
(2009) [10]
F 55 Sensation of hea
and the lower lim
After 2 months,
4. Li et al.
(2012) [5]
F 34 History of tinglin
right side of bod
5. Present
case (2016)
F 48 Pain in the Left p
pain with loss ofThe differential diagnosis encompasses paragangliomas
[14], malignant peripheral nerve sheath tumors (MPNST)
[15, 16], and metastatic tumors [17, 18]. The approach to
the differential diagnosis should consider the clinical find-
ings, imaging, morphologic and IHC features.
Immunohistochemically, ependymomas are character-
ized by a diffuse expression of GFAP and S-100 protein
and can also express epithelial markers such as EMA
[19]. In our case, neoplastic cells expressed both GFAP
and S100 protein, but were negative for EMA. We be-
lieve the EMA was negative due to its low sensitivity
according to other studies that have observed a lower
sensitivity of the 72% [20]. Our aim was to test otherCE of filum terminale
Lesion features
Well circumscribed lumbar intradural
mass at the L4-L5 level.
Well circumscribed enhanced lumbar
mass at the L2-L3 level.
viness around the waist
bs three months earlier.
lumbago.
Well circumscribed intradural tumor.
g and numbness in the
y and weakness.
Cystic tumor.
elvic limb and back
strenght and balance.
Infiltrative mass at the L3-L5.
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ependymomas and that could possibly be extrapolated
to our case. Based in a study published by Lamzabi et al.
[21] in myxopapillary ependymomas that expressed
CD99 in all cases and CD56 was diffusely positive in
88% cases, we attempted the technique. Other IHC stud-
ies have analyzed the expression of bcl-2, p53 and cyclin
D1 in ependymomas and they appear to act as prognos-
tic predictors although results are discordant [22]. To
date, none of these markers has been tested in GCE.
Therefore, we studied the expression of CD99, CD56,
bcl-2, p53, and cyclin D1 to further characterize our
case, which were positive. We believe that these markers
could be useful in the differential diagnosis of these tu-
mors. Since these markers have not been found to co-
express together in other tumors with giant cells such as
paragangliomas, MPNST, malignant melanomas, adrenal
carcinoma, thyroid gland carcinoma or urothelial carcin-
oma giant cell variant. Table 3 summarizes the immuno-
histochemical characteristics of GCE and its differential
diagnosis with other tumors that may have giant cells.
In this location, one of the differential diagnoses in im-
aging studies is the paraganglioma of the filum termi-
nale. They occur in adults between the fourth and sixth
decades of life and are associated to catecholamine
increases that may lead to hypertension [14]. Histologi-
cally, are characterized by nesting of chief cells with
round or oval nuclei with salt and pepper chromatin pat-
tern; however, occasionally they may harbor giant cells
with pseudoinclusions and formation of pseudorosettes.Table 3 Differential diagnosis by immunohistochemistry of GCE wit
Marker GCE Paraganglioma MPNST Met
S-100 protein + + +/- +/-
GFAP + - - -
CD56 + + - -
CD99 + - - -
Bcl-2 + - - -
Cyclin D1 + - - -
Inhibin - - - -
HMB45 - - - +
Melan A - - - +
Chromogranin - + - -
Synaptophysin - + - -
CKAE1/AE3 - - - -
EMA +/- - - -
CK20 - - - -
Uroplakin III - - - -
GATA3 - - - -
PAX5 - - - -
CK cytokeratin, EMA epithelial membrane antigen,GFAP Glial fibrillary acidic proteinBut, nesting cells are more epithelioid-like and by IHC,
chief cells are immunoreactive for chromogranin, synap-
tophysin and CD56, but are CD99 negative [14]. Susten-
tacular cells may also be identified, which are positive
for S-100 protein. Although in our case S-100 protein
was expressed in the neoplastic cells, both small cells
and giant cells, we did not detect chromogranin or synap-
tophysin expression. These findings coupled with normal
serological and urinary levels of catecholamines in our
patient excluded the possibility of a paraganglioma.
Another differential diagnosis to consider by imaging
studies is the MPNST. Although, MPNST of the lumbar
area are exceptionally rare, they usually develop in the
spinal nerve roots and lead to secondary bony changes
[15, 16]. MRI of the lumbosacral spine shows a large
mass originating in the cauda equina with surrounding
bony destruction. These are very aggressive tumors that
recur and metastasize with poor survival [15, 16]. In our
case, the tumor invaded the nerve roots. However, our
patient is currently alive and with no metastatic activity.
By IHC both tumors may express S100 protein and
PAGF [15, 16]. Therefore, it is convenient to use an anti-
body panel, which must include CD56, CD99, bcl-2 and
cyclin D1, which in our case were positive while in the
MPNST are negative.
Metastatic tumors of the intramedullary spinal cord
are rare and cause diagnostic and therapeutic problems.
Since GCE may have pleomorphic giant cells with pseu-
doinclusions, we also considered malignant melanoma,
adrenal carcinoma, thyroid gland carcinoma, andh other tumors that may have giant cells
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The morphologic distinction between a GCE and meta-
static malignant melanoma may be complex. Malignant
melanoma metastases to the intramedullary spinal cord
are extremely rare and usually show multiple lesions
[17]. By IHC, neoplastic cells was HMB45 and Melan-A
negative, therefore that possibility was excluded. On the
other hand, adrenal carcinomas can metastasize any-
where, although metastases to the spinal cord are also
extremely rare [17]. Histologically, they may have neo-
plastic cells with giant nuclei and extensive necrosis. In
our patient the CT showed no evidence of tumors in
either adrenal gland. By IHC, neoplastic cells were nega-
tive for inhibin. Therefore, this possibility was also
excluded. In the preliminary analysis, papillary thyroid
carcinoma was also considered due to the presence of a
focal papillary pattern and cells with nuclear pseudoin-
clusions and oxyphilic cytoplasm [23]. But, serum
thyroid function tests were within normal parameters
and by IHC the neoplastic cells were negative for thyro-
globulin and TTF-1, which this possibility was excluded.
Finally, we also considered a high-grade urothelial
carcinoma variant of giant cells that had metastasized to
the spinal cord. Uroplakin III, GATA3, cytokeratin 20,
and PAX5 haven been reported to be a useful marker in
the identification of an urothelial origin since it is
expressed in neoplastic bladder cells [24, 25]. All these
markers were negative in our patient, so this neoplasia
was also excluded.Conclusions
In conclusion, we report a case of GCE of the filum
terminale characterized by the presence of giant cells
with pleomorphic nuclei and nuclear pseudoinclusions
with slow-growing and an indolente clinical behavior.
The presence of perivascular pseudo-rosettes and epen-
dymal rossettes is a key histologic feature to confirm the
diagnosis of ependymoma. However, due to the presence
of giant cells, it is first necessary to make differential
diagnosis with other entities. In our case the ependymal
origin was suspected in hematoxylin and eosin staining
and confirmed by IHC. In this histological variant is
convenient to use an antibody panel, which must include
GFAP, S-100 protein, EMA, CD56, CD99, bcl-2. An
ependymoma with heterogeneously enhancement on
MRI suggests the presence of an infiltrating non-
encapsulated tumor.Abbreviations
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